The use of trimethoprim in treatment of Streptococcus pyogenes infections has long been discouraged because it was widely believed that this pathogen is resistant to this antibiotic. To gain more insight into the extent and molecular basis of trimethoprim resistance in S. pyogenes we have tested isolates from India and Germany and sought for the factors that conferred the resistance. Resistant isolates were identified in tests for trimethoprim or trimethoprim/sulfamethoxazole (SXT) susceptibility. Resistant isolates were screened for known horizontally transferable trimethoprim insensitive dihydrofolate reductase (dfr) genes dfrG, dfrF, dfrA, dfrD and dfrK. The nucleotide sequence of the intrinsic dfr was determined for resistant isolates lacking the horizontally transferable genes. Based on tentative criteria 69 out of 268 isolates (25.7%) from India were resistant to trimethoprim. Occuring in 42 of the 69 resistant isolates (60.9%) dfrF was more frequent than dfrG (23 isolates, 33.3%) in India. The dfrF-gene was also present in a collection of SXT-resistant isolates from Germany, in which it was the only detected trimethoprim resistance factor. DfrF caused resistance in 4 out of 5 trimethoprim resistant isolates from the German collection. An amino acid substitution in the intrinsic dihydrofolate reductase known from trimethoprim resistant Streptococcus pneumoniae, conferred resistance to S. pyogenes isolates of emm-type 102.2, which lacked other aforementioned dfr genes. Trimethoprim may be more useful in treatment of S. pyogenes infections than previously thought. However, the herein described factors may lead to a rapid development and spread of resistance to this antibiotic agent in S. pyogenes.
Introduction
Trimethoprim is used for the treatment of enteric, respiratory, skin, and urinary tract infections. It acts bacteriostatically by inhibition of the dihydrofolate reductase (DHFR), an enzyme of the folate synthesis pathway. Interference with this pathway inhibits bacterial DNA synthesis. Typically, trimethoprim is used in combination with sulfamethoxazole, a sulphonamide. This combination is also known as cotrimoxazole or SXT. Like other sulphonamides, sulfamethoxazole is an inhibitor of the dihydropteroate synthase, another enzyme of the folate synthesis pathway . Because of early non-standardized antibiotic susceptibility tests, Streptococcus pyogenes was considered as largely resistant to SXT. S. pyogenes is pathogenic in humans, causing a variety of diseases. This spectrum of diseases ranges from pharyngitis, tonsillitis and suppurative skin and soft tissue infections to severe invasive infections and immune sequelae.
Today's knowledge about the pitfalls in SXT susceptibility testing raised doubts on some of the early data and the widespread resistance of S. pyogenes to this combination drug . SXT may be an underestimated alternative to other antibiotics under certain circumstances such as in the treatment of streptococcal skin and soft tissue co-infections with MRSA . However, a re-evaluation of SXT for use in S.
pyogenes infections requires clinical studies and more, reliable data on the spread of resistance. The knowledge about the genes and mutations that confer resistance to resistance in S. pyogenes. In our previous work we report trimethoprim resistance in S. pyogenes due to a dihydrofolate reductase gene dfrG. To our knowledge, no other mutations and genes that confer resistance to trimethoprim or sulphonamides to S. pyogenes have been reported.
Generally, bacterial resistance to trimethoprim is mediated by the following five main mechanisms: (i) a permeability barrier, (ii) a naturally insensitive intrinsic DHFR, (iii) spontaneous mutations in the intrinsic DHFR, (iv) increased production of the sensitive target enzyme by up regulation of gene expression or gene duplication, and 
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Acquired trimethoprim resistance genes in S. pyogenes
Recently, we reported the presence of a trimethoprim resistance determinant dfrG in 
Trimethoprim resistance in SXT-resistant S. pyogenes isolates from Germany
Resistance to SXT (MIC ≥2/38 mg/l) was observed for 37 out of 2371 isolates from Germany (1.6%). These 37 isolates were tested for susceptibility to trimethoprim alone. Due to this pre-selection for SXT-resistance prior to trimethoprim susceptibility testing, a trimethoprim resistance rate for the complete collection of 2371 isolates from Germany could not be determined. Four out of the 37 SXT-resistant isolates were resistant to trimethoprim (MIC >512 mg/l) and positive for dfrF (Tab. 4). Two of these isolates were of emm-type 81, the other two of emm-type 28 and st854, (Fig. 3) . In the agar dilution test for trimethoprim resistance (Fig. 4) the by frequent prescription of this drug in rural settings of India . When considered separately, the resistance rate was higher in Northern India (55.1%) than in Southern India (11.2%) (Tab. 3). A resistance rate for Germany was not determined, as the isolates of this study were pre-seleced for SXT-resistance.
In a previous publication we described a 3.3 kb DNA sequence that contained dfrG and that was integrated into the genome of S. pyogenes emm1-2 isolates. The element was integrated into a sequence that was homologous to SPy_1769. Taken together the herein presented data suggest a considerable horizontal transfer of dfrG and dfrF in S. pyogenes in India.
As reported previously an amino acid substitution from isoleucine to leucine in position 100 of the intrinsic DHFR caused trimethoprim resistance in S. pneumoniae.
In our study the same mutation conferred trimethoprim resistance to all 4 S.
pyogenes isolates of emm-type 102.2 that were isolated in India. The isolates differed in their MIC, which may be due to differences in the biosynthesis of the enzyme (Fig. 2) . Taking previous observations into account, one can conclude that a single mutation either in the intrinsic dihydrofolate reductase gene or in the dihydropteroate synthase gene is sufficient to diminish the susceptibility of S.
pyogenes to trimethoprim or sulphonamides, respectively.
Recommendations against the use of SXT for S. pyogenes infections continue in the belief that the pathogen is intrinsically resistant to this drug. As discussed recently by 
